O
Omar Wever-Pinzon
Researcher at University of Utah
Publications - 103
Citations - 2810
Omar Wever-Pinzon is an academic researcher from University of Utah. The author has contributed to research in topics: Heart failure & Ventricular assist device. The author has an hindex of 22, co-authored 88 publications receiving 1893 citations. Previous affiliations of Omar Wever-Pinzon include Veterans Health Administration & LDS Hospital.
Papers
More filters
Journal ArticleDOI
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Iacopo Olivotto,Artur Oreziak,Roberto Barriales-Villa,Theodore P. Abraham,Ahmad Masri,Pablo García-Pavía,Pablo García-Pavía,Sara Saberi,Neal K. Lakdawala,Matthew T. Wheeler,Anjali T. Owens,Milos Kubanek,Wojciech Wojakowski,Morten Kvistholm Jensen,Juan Ramón Gimeno-Blanes,Kia Afshar,Jonathan Myers,Jonathan Myers,Sheila M. Hegde,Scott D. Solomon,Amy J. Sehnert,David Zhang,Wanying Li,Mondira Bhattacharya,Jay M. Edelberg,Cynthia Burstein Waldman,Steven J. Lester,Andrew Wang,Carolyn Y. Ho,Daniel Jacoby,Jozef Bartunek,Antoine Bondue,Emeline Van Craenenbroeck,David Zemanek,Morten Søndergaard Jensen,Jens Mogensen,Jens Jakob Thune,Philippe Charron,Albert Hagège,Olivier Lairez,Jean Noël Trochu,Christoph Axthelm,Hans Dirk Duengen,Norbert Frey,Veselin Mitrovic,Michael Preusch,Jeanette Schulz-Menger,Tim Seidler,Michael Arad,Majdi Halabi,Amos Katz,Daniel Monakier,Offir Paz,Samuel Viskin,Donna R. Zwas,Hans-Peter Brunner-La Rocca,Michelle Michels,Dariusz Dudek,Zofia Oko-Sarnowska,Nuno Cardim,Helder Pereira,Pablo García Pavia,Juan Ramon Gimeno Blanes,Rafael Hidalgo Urbano,Luis Miguel Rincón Diaz,Perry M. Elliott,Zaheer Yousef,Theodore Abraham,Paulino Alvarez,Richard G. Bach,Richard C. Becker,Lubna Choudhury,David Fermin,John L. Jefferies,Christopher M. Kramer,Neal K. Lakdawala,Steven Lester,Ali J. Marian,Mathew S. Maurer,Sherif F. Nagueh,David R. Owens,Florian Rader,Mark V. Sherrid,Jamshid Shirani,John Symanski,Aslan T. Turer,Omar Wever-Pinzon,Timothy C. Wong,Mohamad H. Yamani +88 more
TL;DR: Treatment with mavacamten improved exercise capacity, LVOT obstruction, NYHA functional class, and health status in patients with obstructive hypertrophic cardiomyopathy and highlights the benefits of disease-specific treatment for this condition.
Journal ArticleDOI
Pulsatility and the Risk of Nonsurgical Bleeding in Patients Supported With the Continuous-Flow Left Ventricular Assist Device HeartMate II
Omar Wever-Pinzon,Craig H. Selzman,Stavros G. Drakos,Abdulfattah Saidi,Gregory J. Stoddard,Edward M. Gilbert,Mohamed Labedi,Bruce B. Reid,Erin Davis,Abdallah G. Kfoury,Dean Y. Li,Josef Stehlik,Feras Bader +12 more
TL;DR: In this paper, the effects of different degrees of pulsatility on the incidence of nonsurgical bleeding were assessed by means of the LVAD parameter pulsatility index (PI) and by the echocardiographic assessment of aortic valve opening during the first 3 months of LVAD support.
Journal ArticleDOI
Magnitude and Time Course of Changes Induced by Continuous-Flow Left Ventricular Assist Device Unloading in Chronic Heart Failure: Insights Into Cardiac Recovery
Stavros G. Drakos,Stavros G. Drakos,Omar Wever-Pinzon,Craig H. Selzman,Craig H. Selzman,Edward M. Gilbert,Rami Alharethi,Bruce B. Reid,Abdulfattah Saidi,Nikolaos A. Diakos,S. Stoker,Erin Davis,Matthew A. Movsesian,Dean Y. Li,Josef Stehlik,Abdallah G. Kfoury,Ucar Investigators +16 more
TL;DR: Continuous-flow LVAD unloading induced in a subset of patients, both ischemic and nonischemic, early improvement in myocardial structure and systolic and diastolic function that was largely completed within 6 months, with no evidence of subsequent regression.
Journal ArticleDOI
Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors.
Harikrishna Makani,Franz H. Messerli,Jorge Romero,Omar Wever-Pinzon,Aleksander Korniyenko,Ronaldo Sevilla Berrios,Sripal Bangalore +6 more
TL;DR: Investigation of randomized clinical trials from 1980 to October 2011 found incidence of angioedema with ARBs and DRI was <1/2 than that with ACE inhibitors and not significantly different from placebo.
Journal ArticleDOI
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy
Carolyn Y. Ho,Matthew E Mealiffe,Richard G. Bach,Mondira Bhattacharya,Lubna Choudhury,Jay M. Edelberg,Sheila M. Hegde,Daniel Jacoby,Neal K. Lakdawala,Steven J. Lester,Yanfei Ma,Ali J. Marian,Sherif F. Nagueh,Anjali T. Owens,Florian Rader,Sara Saberi,Amy J. Sehnert,Mark V. Sherrid,Scott D. Solomon,Andrew Wang,Omar Wever-Pinzon,Timothy C. Wong,Stephen B. Heitner +22 more
TL;DR: Mavacamten, a novel myosin inhibitor, was well tolerated in most subjects with symptomatic nHCM and treatment was associated with a significant reduction in NT-proBNP and cTnI, suggesting improvement in myocardial wall stress.